Cardiology pp 141-152 | Cite as

Clinical Trials with Antiaggregating Agents in Thrombosis

  • M. Verstraete

Abstract

Many agents capable of interfering with normal platelet function in vitro have been described in recent years; most are nonsteroidal anti-inflammatory agents. Not all these compounds have been shown to affect platelet aggregation and adhesiveness in experimental animals, but since animals do not develop spontaneous thrombosis, the relevance of such experiments to clinical medicine is rather tenuous. The only drugs suppressing platelet function that have been evaluated in clinical trials are aspirin, sulfinpyrazone, dipyridamole, hydroxychoroquine, Clofibrate, flurbiprofen, and lidocaine, all of which were originally used for other therapeutic purposes. Even today one still has a poor understanding of the relationship between some of their effects on platelets and a potential antithrombotic effect. It is even uncertain whether the latter property is due to their impact on platelets or to some other unknown mode of action.

Keywords

Regular Aspirin AORTOCORONARY Bypass Surgery Sudden Death Rate Coronary Drug Project Research Group Affect Platelet Aggregation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Altman, R., Boullon, F., Rouvier, J., Raca, R., De la Fuente, L., and Favorolo, R., 1976, Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves, J. Thorac. Card. Surg., 72:127.Google Scholar
  2. Anturane Reinfarction Trial Research Group, 1978, Sulfinpyrazone in the prevention of cardiac death after myocardial infarction, N. Engl. J. Med., 298:289.CrossRefGoogle Scholar
  3. Anturane Reinfarction Trial Research Group, 1980, Sulfinpyrazone in the prevention of sudden death after myocardial infarction, N. Engl. J. Med., 302:250.CrossRefGoogle Scholar
  4. Anturane Reinfarction Trial Policy Committee, 1982, The Anturane reinfarction trial: reevaluation of outcome, N. Engl. J. Med., 306:1005.CrossRefGoogle Scholar
  5. Anturane Reinfarction Italian Study, 1982, Sulphinpyrazone in postmyocardial infarction, Lancet, i:237.Google Scholar
  6. Arrants, J. E., Hairston, P., and Lee, W. H. Jr., 1970, Use of dipyridamole (Persantine) in preventing thromboembolism following valve replacement (Abstract), Chest, 58:275.Google Scholar
  7. Aspirin Myocardial Infarction Study Research Group, 1980, A randomized controlled trial of aspirin in persons recovered from myocardial infarction, JAMA, 243:661.CrossRefGoogle Scholar
  8. Bierme, R., Boneu, B., Giraud, B., and Pris, J., 1972, Aspirin and recurrent painful toes and fingers in thrombocythaemia, Lancet, i:431.Google Scholar
  9. Blakely, J. A., and Gent, M., 1975, Platelets, drugs and longevity in a geriatric population, in: “Platelets, Drugs and Thrombosis”, Hirsh, J., Cade, J. F., Gallus, A. S., and Schönbaum, E., eds., Karger, Basel, p. 284.Google Scholar
  10. Blakely, J. A., and Pogoriler, G., 1977, A prospective trial of sulfinpyrazone after peripheral vascular surgery, Proc. VIth Congr. Int. Soc. Thrombosis and Hemostasis, Philadelphia, p. 238.Google Scholar
  11. Bollinger, A., Fitschy, J., Torres, C., and Piquerez, M. J., 1978, Thrombozytenaggregationshemmer nach offener oder halfoffener Endarteriektomie; Vorläufige Resultate einer prospektiven Studie, VASA, 7:82.Google Scholar
  12. Boston Collaborative Drug Surveillance Group, 1974, Regular aspirin intake and acute myocardial infarction, Brit. Med. J., 1:440.CrossRefGoogle Scholar
  13. Breddin, K., Loew, D., Lechner, K., Ueberla, K., and Walter, E., 1980, Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon, Hemostasis, 9:325.Google Scholar
  14. Canadian Cooperative Study Group, 1978, A randomized trial of aspirin and sulfinpyrazone in threatened stroke, N. Engl. J. Med., 299:53.CrossRefGoogle Scholar
  15. Committee of Principal Investigators, 1978, A cooperative trial on the primary prevention of ischemic heart disease using Clofibrate, Brit. Heart J., 40:1069.CrossRefGoogle Scholar
  16. Committee of Principal Investigators, 1980, WHO cooperative trial on primary prevention of ischemic heart disease using Clofibrate to lower serum cholesterol: mortality follow-up, Lancet, ii:379.Google Scholar
  17. Coronary Drug Project Research Group, 1975, Clofibrate and niacin in coronary heart disease, JAMA, 27:360.Google Scholar
  18. Dale, J., Myhre, E., Storstein, O., Stormorken, H., and Efskin, D. L., 1977, Prevention of arterial thromboembolism with acetylsalicylic acid. A controlled clinical study in patients with aortic ball valves, Am. Heart J., 94:101.PubMedCrossRefGoogle Scholar
  19. Ehresmann, V., Alemany, J., and Loew, D., 1977, Prophylaxe von Rezidivverschlussen nach Revascularisation — Eingriffen mit Acetylsalicylsaure, Med. Welt., 28:1157.PubMedGoogle Scholar
  20. Elwood, P. C., Cochrane, A. L., Burr, M. L., Sweetnam, P. M., Williams, G., Welsby, E., Hughes, S. J., and Renton, R., 1974, A randomized controlled trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction, Brit. Med. J., 1:436.PubMedCrossRefGoogle Scholar
  21. Elwood, P. C., and Sweetnam, P. M., 1979, Aspirin and secondary mortality after myocardial infarction, Lancet, i :1313.CrossRefGoogle Scholar
  22. Fields, W. S., Lemak, N. A., Frankowski, R. F., and Hardy, R. J., 1977, 1978, Controlled trial of aspirin in cerebral ischemia, Stroke, 8:301; 9:309.CrossRefGoogle Scholar
  23. Gent, A. E., Brook, C. G. D., Foley, T. H., and Miller, T. N., 1968, Dipyridamole. A controlled trial of its effect in acute myocardial infarction, Brit. Med. J., 4:366.PubMedCrossRefGoogle Scholar
  24. Goldberg, I. D., Stemerman, M. B., and Schnipper, L. E., 1979, Vascular smooth muscle cell kinetics: a new assay for studying patterns of cellular proliferation in vivo, Science, 205:920.PubMedCrossRefGoogle Scholar
  25. Groupe de Recherce PACTE, 1978, Prévention des accidents thrombo-emboliques systémiques chez les porteurs de prothèses val-vulaires artificielles: essai coopératif contrôlé du dipyridamole, Coeur, 19:915.Google Scholar
  26. Hall, R. J., Garcia, E., Al-Bassam, M. S., and Dawson, J. T., 1974, Aortocoronary bypass surgery 1969–1973; Review of 2,566 patients, Cardiovasc. Dis. Bull., 1:74.Google Scholar
  27. Hammond, E. C., and Garfinkel, L., 1975, Aspirin and coronary heart disease: findings of a prospective study, Brit. Med. J., 2:269.PubMedCrossRefGoogle Scholar
  28. Heikinheimo, R., and Jarvinen, K., 1971, Acetylsalicylic acid and arteriosclerotic thromboembolic diseases in the aged, J. Amer. Geriat. Soc, 19:403.PubMedGoogle Scholar
  29. Hennekens, C. H., Karlson, L. K., and Rosner, B., 1978, A case-control study of regular aspirin use and coronary deaths, Circulation, 58:35.PubMedCrossRefGoogle Scholar
  30. Herman, B., de Waard, F., and Colette, H. J. A., 1981, Unexpected trends in the analysis of a questionnaire and interview procedure to detect transient cerebral ischemic attack in a female population, Clin. Neurol. Neurosurg., 83:225.PubMedCrossRefGoogle Scholar
  31. Isom, O. W., Williams, C. D., Falk, E. A., Spencer, F. C., and Glassman, E., 1973, Evaluation of anti-coagulant therapy in cloth-covered prosthetic valves, Circulation, suppl. III:48.Google Scholar
  32. Jick, H., and Miettinen, O. S., 1976, Regular aspirin use and myocardial infarction, Brit. Med. J., 1:1057.PubMedCrossRefGoogle Scholar
  33. Katsumara, T., Kusaba, A., Shionoya, S., Kamiya, K., Myaucchi, Y., and Nishimura, A., 1980, Therapeutic effects of ticlopidine, a new inhibitor of platelet aggregation in chronic arterial occlusive disease, Blood Vessels, 11:152.CrossRefGoogle Scholar
  34. Krasno, L. R., and Kidera, G. J., 1972, Clofibrate in coronary heart disease, JAMA, 219:845.PubMedCrossRefGoogle Scholar
  35. McNicol, G. P., 1980, Anti-platelet drugs in the secondary prevention of myocardial infarction, Lancet, ii:736.CrossRefGoogle Scholar
  36. Meyer, J. S., Charney, J. Z., Rivera, V. M., and Mathew, N. J., 1971, Cerebral embolization: prospective clinical analysis of 42 cases, Stroke, 2:541.PubMedCrossRefGoogle Scholar
  37. Mitchell, J. R. A., 1980, Secondary prevention of myocardial infarction — the present state of the ART, Brit. Med. J., 280:1128.PubMedCrossRefGoogle Scholar
  38. Newcastle-upon-Tyne Physicians, 1971, Trial of Clofibrate in the treatment of ischemic heart disease, Brit. Med. J., 4:767.CrossRefGoogle Scholar
  39. Oblath, R. W., Buckley, F. O., Green, R. M., Schwartz, S. E., and de Weese, J. A., 1978, Prevention of anastomic neointimal fibrous hyperplasia in femoral bypass by aspirin and dipyridamole, Surgery, 84:37.PubMedGoogle Scholar
  40. Olsson, J. E., Brechter, C., Bäcklund, H., Krook, H., Müller, R., Nitelius, E., Olsson, O., and Tornberg, A., 1980, Anticoagulant vs antiplatelet therapy as prophylactive cerebral infarction in transient ischemic attacks, Stroke, 2:4.CrossRefGoogle Scholar
  41. Pell, E., 1975, Essai clinique contrôlé du Dipyridamole dans le traitement préventif des accidents thromboemboliques chez les porteurs de prothèses valvulaires, Thèse, Lyon.Google Scholar
  42. Persantine-Aspirin Reinfarction Study Research Group, 1980, Persantine and aspirin in coronary heart disease, Circulation, 62:449.CrossRefGoogle Scholar
  43. Preston, F. E., Emmanuel, I. G., Winfield, D. A., and Malia, R. G., 1974, Essential thrombocythemia and peripheral gangrene, Brit. Med. J., 3:548.PubMedCrossRefGoogle Scholar
  44. Research Committee of the Scottish Society of Physicians, 1971, Ischemic heart disease: a secondary prevention trial using Clofibrate, Brit. Med. J., 4:775.CrossRefGoogle Scholar
  45. Rodvian, R., and Salzman, E. W., 1978, Thrombotic and hemorrhagic problems in surgery, Thrombos. Hemost., 39:254.Google Scholar
  46. Sullivan, J. M., Harken, D. E., and Gorlin, R., 1971, Pharmacologic control of thromboembolic complications of cardiac valve replacement, N. Engl. J. Med., 284:1391.PubMedCrossRefGoogle Scholar
  47. Sutton, M. G., and John, S. T., 1978, Anticoagulation and Björk-Shiley prosthesis. Experience of 390 patients. Brit. Heart J., 40:558.PubMedCrossRefGoogle Scholar
  48. Vreeken, J., and van Aken, W. G., 1971, Spontaneous aggregation of blood platelets as a cause of idiopathic thrombosis and recurrent painful toes and fingers, Lancet, ii:1394.CrossRefGoogle Scholar
  49. Wilcox, R. G., Richardson, D., Hampton, J. R., Mitchell, J. R. A., and Banks, D. C., 1980, Sulphinpyrazone in acute myocardial infarction: studies on cardiac rhythm and renal function, Brit. Med. J., 2:531.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1984

Authors and Affiliations

  • M. Verstraete
    • 1
  1. 1.Center for Thrombosis and Vascular Research Department of Medical ResearchUniversity of LeuvenLeuvenBelgium

Personalised recommendations